Novartis Ag (NVS) Cash & Equivalents Growth (1y) (2016 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash & Equiv. Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
70.76% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-43.63% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
81.47% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-38.27% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
36.64% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
-3.76% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
19.09% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-11.96% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
-9.03% |
| Date | Value |
|---|
| Dec 31, 2025 |
965.70% |
| Jun 30, 2025 |
-15.78% |
| Dec 31, 2024 |
-98.19% |
| Sep 30, 2024 |
-63.58% |
| Jun 30, 2024 |
-34.14% |
| Dec 31, 2023 |
78.17% |
| Sep 30, 2023 |
636.36% |
| Jun 30, 2023 |
231.03% |
| Dec 31, 2022 |
-39.41% |
| Sep 30, 2022 |
780.00% |
| Jun 30, 2022 |
-29.16% |
| Mar 31, 2022 |
1,066.67% |
| Dec 31, 2021 |
28.46% |
| Jun 30, 2021 |
-13.52% |
| Mar 31, 2021 |
-92.11% |
| Dec 31, 2020 |
-13.08% |
| Jun 30, 2020 |
-55.41% |
| Mar 31, 2020 |
-84.77% |
| Dec 31, 2019 |
-16.27% |
| Jun 30, 2019 |
49.79% |
| Dec 31, 2018 |
49.79% |
| Jun 30, 2018 |
17.01% |
| Dec 31, 2017 |
26.44% |
| Dec 31, 2016 |
49.91% |
